• Insilico Medicine flagged first-in-human Phase I data for ISM6331, an AI-designed pan-TEAD inhibitor, accepted for rapid oral presentation at ESMO 2026.
• Results have not been presented yet; the talk is scheduled for Oct. 25, 2026 in Madrid.
• The study is assessing safety, tolerability, drug behavior in the body, and early signs of anti-tumor activity in mesothelioma and other advanced solid tumors.
• ISM6331 previously received FDA orphan drug designation for mesothelioma in August 2024, supporting its development path in a niche oncology market.
• The first patient was dosed in the global multicenter Phase I trial in January 2025, marking progression from preclinical work into clinical testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12256703), on July 27, 2026, and is solely responsible for the information contained therein.